299428-04-9

Basic information

• Product Name: alpha,alpha-Dimethyl-1-(phenylmethyl)-4-piperidinemethanol
• Synonyms: 2-(1-Benzylpiperidin-4-yl)propan-2-ol;alpha,alpha-Dimethyl-1-(phenylmethyl)-4-piperidinemethanol;2-(1-Benzylpiperidin-4-yl)-2-propanol
• CAS NO: 299428-04-9
• Molecular Formula: C₁₅H₂₃NO
• Molecular Weight: 233.34922
• Mol File: 299428-04-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 331℃
• Flash Point: 139℃
• Appearance: /
• Density: 1.046
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.548
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: alpha,alpha-Dimethyl-1-(phenylmethyl)-4-piperidinemethanol(CAS DataBase Reference)
• NIST Chemistry Reference: alpha,alpha-Dimethyl-1-(phenylmethyl)-4-piperidinemethanol(299428-04-9)
• EPA Substance Registry System: alpha,alpha-Dimethyl-1-(phenylmethyl)-4-piperidinemethanol(299428-04-9)

Safety Data

• Hazardous Substances Data: 299428-04-9(Hazardous Substances Data)

Usage

General Description

Alpha,alpha-Dimethyl-1-(phenylmethyl)-4-piperidinemethanol is a chemical compound with a complex structure. It is a piperidine derivative with a methyl group attached to the nitrogen atom and a phenylmethyl group at the alpha carbon position. alpha,alpha-Dimethyl-1-(phenylmethyl)-4-piperidinemethanol has potential pharmaceutical applications and may act as a central nervous system depressant. It is commonly used as an intermediate in the synthesis of various pharmaceuticals and may also have applications in organic chemistry research. However, it is important to handle this compound with caution as it may have toxic or hazardous properties.

InChI:InChI=1/C15H23NO/c1-15(2,17)14-8-10-16(11-9-14)12-13-6-4-3-5-7-13/h3-7,14,17H,8-12H2,1-2H3

Upstream product

• 75-16-1 methylmagnesium bromide 
• 24228-40-8 N-benzyl isonipecotic acid ethyl ester 
• 917-54-4 methyllithium 
• 10315-06-7 1-benzylpiperidine-4-carboxylic acid methyl ester 
• 1126-09-6 4-carbethoxypiperidine 
• 100-39-0 benzyl bromide 

Downstream Products

• 22990-34-7 2-(piperidin-4-yl)propan-2-ol 

Relevant articles and documents

Use of structure based design to increase selectivity of pyridyl-cinnoline phosphodiesterase 10A (PDE10A) inhibitors against phosphodiesterase 3 (PDE3)

We report our successful effort to increase the PDE3 selectivity of PDE10A inhibitor pyridyl cinnoline 1 using a combination of computational modeling and structural-activity relationship investigations. An analysis of the PDE3 catalytic domain compared to the co-crystal structure of cinnoline analog 1 in PDE10A revealed two areas of structural differences in the active sites and suggested areas on the scaffold that could be modified to exploit those unique structural features. Once SAR established the cinnoline as the optimal scaffold, modifications on the methoxy groups of the cinnoline and the methyl group on the pyridine led to the discovery of compounds 33 and 36. Both compounds achieved significant improvement in selectivity against PDE3 while maintaining their PDE10A inhibitory activity and in vivo metabolic stability comparable to 1.

PHOSPHODIESTERASE 10 INHIBITORS

The present invention is directed to compounds, useful as PDE10 inhibitors, having the formula where R1,R2, R3, R4, X, Y and z are as defined herein, pharmaceutical compositions containing such compounds. and processes for preparing such compounds. The invention is also directed to methods of treating diseases mediated by PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like

PHARMACEUTICAL COMPOUNDS

Fused pyrimidines of formula (I); wherein A represents a thiophene or furan ring; n is 1 or 2; R1 is a group of formula (II); wherein m is 0 or 1; R30 is H or C1-C6 alkyl; R4 and R5 form, together with the N atom to which they are attached, a 5- or 6-membered saturated N-containing heterocyclic group which includes 0 or 1 additional heteroatoms selected from N, S and O, which may be fused to a benzene ring and which is unsubstituted or substituted; or one of R4 and R5 is alkyl and the other is a 5- or 6-membered saturated N-containing heterocyclic group as defined above or an alkyl group which is substituted by a 5- or 6-membered saturated N-containing heterocyclic group as defined above; R2 is selected from formula (a); wherein R6 and R7 form, together with the nitrogen atom to which they are attached, a morpholine, thiomorpholine, piperidine, piperazine, oxazepane or thiazepane group which is unsubstituted or substituted; and formula (b); wherein Y is a C2-C4 alkylene chain which contains, between constituent carbon atoms of the chain and/or at one or both ends of the chain, 1 or 2 heteroatoms selected from O, N and S, and which is unsubstituted or substituted; and R3 is an indazole group which is unsubstituted or substituted; and the pharmaceutically acceptable salt thereof have activity as inhibitors of P13K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with P13 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.